Cefozopran (hydrochloride)

Cefozopran (SCE-2787) hydrochloride is a semi-synthetic, parenteral, fourth-generation cephalosporin. Cefozopran hydrochloride, an antibiotic, has a broad spectrum of antibacterial activity, inhibiting most of the gram-negative and gram-positive organisms[1][2].

Product Specifications

CAS Number

[113981-44-5]

Product Name Alternative

SCE-2787 hydrochloride

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Cefozopran-hydrochloride.html

Purity

97.66

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

[H]Cl.[O-]C(C(N1[C@@]2([H])[C@H](NC(/C(C3=NSC(N)=N3)=N\OC)=O)C1=O)=C(CS2)C[N+]4=C(C=CC=N5)N5C=C4)=O

Molecular Formula

C19H18ClN9O5S2

Molecular Weight

551.99

Precautions

H302, H315, H319, H335

References & Citations

[1]Sato T, et al. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatr Blood Cancer. 2008;51 (6) :774-777.|[2]Iizawa Y, et al. Therapeutic effect of cefozopran (SCE-2787), a new parenteral cephalosporin, against experimental infections in mice. Antimicrob Agents Chemother. 1993;37 (1) :100-105.